SCHEMBL496554

SCHEMBL496554

CC1(C)C(=O)Nc2cc(N)ccc21

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK2 Q15119 1/20 0.55
PDK4 Q16654 1/20 0.55
MAPK14 Q16539 4/20 0.47
CA9 Q16790 1/20 0.44
ATAD2 Q6PL18 1/20 0.43
PGR P06401 7/20 0.42
BMPR1B O00238 1/20 0.41
BMPR1A P36894 1/20 0.41
TGFBR1 P36897 1/20 0.41
ACVRL1 P37023 1/20 0.41
ACVR1 Q04771 1/20 0.41
PDE3B Q13370 2/20 0.41
PDE3A Q14432 2/20 0.41
PDE4A P27815 1/20 0.38
PDE4B Q07343 1/20 0.38
PDE4C Q08493 1/20 0.38
PDE4D Q08499 1/20 0.38
HTR6 P50406 1/20 0.38
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30539488 1.00 PDK2 (0.55) PDK2PDK4MAPK14CA9ATAD2
Hydrochloric Acid SCHEMBL7276702 0.98 PDK2 (0.53) PDK2PDK4MAPK14CA9ATAD2
SCHEMBL520415 0.85 PDK2 (0.55) PDK2PDK4ATAD2PGRPDE3B
Hydrochloric Acid SCHEMBL31507926 0.83 PDK2 (0.53) PDK2PDK4ATAD2PGRPDE3B
SCHEMBL14211046 0.81 CA9 (0.42) PDK2PDK4MAPK14CA9HTR6
SCHEMBL7433946 0.78 PDK2 (0.57) PDK2PDK4MAPK14CA9ATAD2
SCHEMBL18413758 0.78 CHEK1 (0.47) PDK2PDK4CA9PGRPDE3B
SCHEMBL2102219 0.78 PDK2 (0.39) PDK2PDK4MAPK14CA9MEN1
SCHEMBL15577573 0.78 PDK2 (0.47) PDK2PDK4MAPK14ATAD2PGR
SCHEMBL2144278 0.77 PDK2 (0.55) PDK2PDK4MAPK14ATAD2PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250320184-A1 SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF SIRONAX LTD (KY) 2025-10-16 US disclosed
WO-2025090514-A1 COVALENT SARM1 INHIBITORS NURA BIO, INC. (US) 2025-05-01 WO disclosed
US-12054488-B2 Pyrazolopyrimidine compound and preparation method therefor and use thereof in preparation of anti-cancer drug SUZHOU RAYMON PHARMACEUTICALS COMPANY, LTD. (CN) 2024-08-06 US disclosed
CN-110950868-B Pyrazolopyrimidine compound, preparation method thereof and application of pyrazolopyrimidine compound in preparation of anti-cancer drugs 苏州锐明新药研发有限公司 2022-05-13 CN disclosed
US-20220106316-A2 PYRAZOLOPYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF IN PREPARATION OF ANTI-CANCER DRUG SUZHOU RAYMON PHARMACEUTICALS COMPANY, LTD. (CN) 2022-04-07 US disclosed
US-20210340146-A1 PYRAZOLOPYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF IN PREPARATION OF ANTI-CANCER DRUG SUZHOU RAYMON PHARMACEUTICALS COMPANY LTD (CN) 2021-11-04 US disclosed
US-20210340146-A1 PYRAZOLOPYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF IN PREPARATION OF ANTI-CANCER DRUG SUZHOU RAYMON PHARMACEUTICALS COMPANY LTD (CN) 2021-11-04 US disclosed
CN-110950868-A Pyrazolopyrimidine compound, preparation method thereof and application thereof in preparing anti-cancer drugs 苏州锐明新药研发有限公司 2020-04-03 CN disclosed
WO-2020063636-A1 PYRAZOLOPYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF IN PREPARATION OF ANTI-CANCER DRUG 苏州锐明新药研发有限公司 2020-04-02 WO disclosed
WO-2020063636-A1 PYRAZOLOPYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF IN PREPARATION OF ANTI-CANCER DRUG 苏州锐明新药研发有限公司 2020-04-02 WO disclosed
US-4963686-A INTERMEDIATES FOR INOTROPIC AGENTS BOEHRINGER MANNHEIM GMBH (DE) 1990-10-16 US disclosed
EP-0216165-B1 BENZODIPYRROLES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS Roche Diagnostics GmbH (DE) 1989-11-23 EP disclosed
US-4874756-A CARDIOVASCULAR DISORDERS BOEHRINGER MANNHEIM GMBH (DE) 1989-10-17 US disclosed
EP-0327986-A2 Medicaments containing lactams, substituted lactams and process for their preparation Roche Diagnostics GmbH (DE) 1989-08-16 EP disclosed
US-4835280-A Indoline compounds for synthesis of pharmaceutically active pyrrolobenzimidazoles BOEHRINGER MANNHEIM GMBH (DE) 1989-05-30 US disclosed
US-4810801-A Pyrrolobenzimidazoles, pharmaceutical compositions containing them, and use of them to treat certain heart and circulatory diseases BOEHRINGER MANNHEIM GMBH (DE) 1989-03-07 US disclosed
CN-85103724-B Process for preparing pyrrolobenzimidazoles 曼海姆伯灵格股份公司 1988-07-06 CN disclosed
EP-0216165-A1 Benzodipyrroles, processes for their preparation and pharmaceutical compositions containing these compounds Roche Diagnostics GmbH (DE) 1987-04-01 EP disclosed
CN-85103724-A The method for preparing novel pyrrolo-benzoglyoxaline 1986-07-02 CN disclosed
EP-0161632-A2 Pyrrolo-benzimidazoles, process for their preparation, medicaments containing them and intermediates Roche Diagnostics GmbH (DE) 1985-11-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250320184-A1 SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF SARM1, SMN1; SMN2, ADRM1 PDK2 3167/4885PDK4 3533/4885MAPK14 2680/4885
US-20220106316-A2 PYRAZOLOPYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF IN PREPARATION OF ANTI-CANCER DRUG PIK3CA, PIK3CD, PIK3R5 PDK2 140/4885PDK4 361/4885MAPK14 60/4885
US-20210340146-A1 PYRAZOLOPYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF IN PREPARATION OF ANTI-CANCER DRUG PIK3CA, PIK3CD, PIK3R5 PDK2 140/4885PDK4 361/4885MAPK14 60/4885
US-12054488-B2 Pyrazolopyrimidine compound and preparation method therefor and use thereof in preparation of anti-cancer drug PIK3CA, PIK3CD, PIK3R5 PDK2 140/4885PDK4 361/4885MAPK14 60/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.